CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 258 enrolled
Drug / intervention
Sigh +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03201263
NCT03201263N/ACompleted

PRessure suppOrT vEntilation + Sigh in aCuTe hypoxemIc respiratOry Failure patieNts (PROTECTION): a Pilot Randomized Controlled Trial

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·interventional·Posted Jun 28, 2017·Updated Apr 23, 2021

In Brief

A clinical study evaluating Sigh and Standard of care for Respiratory Failure and 2 related conditions. Completed, enrolled 258 participants across 19 sites in 7 countries.

Detailed Summary

Mortality of intubated acute hypoxemic respiratory failure (AHRF) and acute respiratory distress syndrome (ARDS) patients remains considerably high (around 40%) (Bellani 2016). Early implementation of a specific mechanical ventilation mode that enhances lung protection in patients with mild to moderate AHRF and ARDS on spontaneous breathing may have a tremendous impact on clinical practice. Previous studies showed that the addition of cyclic short recruitment maneuvers (Sigh) to assisted mechanical ventilation: improves oxygenation without increasing ventilation pressures and FiO2; decreases the tidal volumes by decreasing the patient's inspiratory drive; increases the EELV by regional alveolar recruitment; decreases regional heterogeneity of lung parenchyma; decreases patients' inspiratory efforts limiting transpulmonary pressure; improves regional compliances. Thus, physiologic studies generated the hypothesis that addition of Sigh to pressure support ventilation (PSV, the most common assisted mechanical ventilation mode) might decrease ventilation pressures and FiO2, and limit regional lung strain and stress through various synergic mechanisms potentially yielding decreased risk of VILI, faster weaning and improved clinical outcomes. The investigators conceived a pilot RCT to verify clinical feasibility of the addition of Sigh to PSV in comparison to standard PSV. The investigators will enrol 258 intubated spontaneously breathing patients with mild to moderate AHRF and ARDS admitted to the ICU. Patients will be randomized through an online automatic centralized and computerized system to the following study groups (1:1 ratio): * PSV group: will be treated by protective PSV settings until day 28 or death or performance of spontaneous breathing trial (SBT); * PSV+Sigh group: will be treated by protective PSV settings with the addition of Sigh until day 28 or death or performance of spontaneous breathing trial (SBT). Indications on ventilation settings, weaning, spontaneous breathing trial and rescue treatment will be specified.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina, France, Germany, Greece, Italy, Spain, United Kingdom

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJun 28, 2017
Enrollment StartDec 20, 2017
Primary CompletionMay 9, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.0 years ago

Interventions

Sighprocedure

Application of cyclic pressure control breath delivered at 30 cmH2O for 3 seconds once per minute in patients undergoing pressure support ventilation

Standard of careprocedure

Standard of care